Adaptimmune   Report issue

For profit Phase 1 Phase 2
Founded: Oxton United Kingdom (2008)

Organization Overview

First Clinical Trial
2009
NCT00991224
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Adaptimmune